Head to Head Analysis: Natus Medical (BABY) versus Its Competitors
Natus Medical (NASDAQ: BABY) is one of 83 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it contrast to its rivals? We will compare Natus Medical to related businesses based on the strength of its analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.
This is a summary of recent ratings and price targets for Natus Medical and its rivals, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Natus Medical Competitors||267||1850||3312||105||2.59|
Natus Medical currently has a consensus target price of $48.00, suggesting a potential upside of 13.21%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 7.21%. Given Natus Medical’s higher possible upside, equities research analysts clearly believe Natus Medical is more favorable than its rivals.
Volatility & Risk
Natus Medical has a beta of 0.89, indicating that its share price is 11% less volatile than the S&P 500. Comparatively, Natus Medical’s rivals have a beta of 0.90, indicating that their average share price is 10% less volatile than the S&P 500.
Earnings & Valuation
This table compares Natus Medical and its rivals revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Natus Medical||$445.49 million||$48.00 million||-471.06|
|Natus Medical Competitors||$2.06 billion||$438.96 million||-76.08|
Natus Medical’s rivals have higher revenue and earnings than Natus Medical. Natus Medical is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Insider & Institutional Ownership
94.4% of Natus Medical shares are owned by institutional investors. Comparatively, 51.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 5.5% of Natus Medical shares are owned by insiders. Comparatively, 18.7% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This table compares Natus Medical and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Natus Medical Competitors||-328.39%||-35.89%||-12.62%|
Natus Medical rivals beat Natus Medical on 7 of the 13 factors compared.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. The Company is organized into three strategic business units: Neurology, Newborn Care and Otometrics.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.